Immunocore To Tap HTA Advice To Ensure IMCgp100 Success
This article was originally published in Scrip
British immunotherapy specialist Immunocore Limited plans to make full use of the scientific advice national regulators are offering to help it progress its lead product IMCgp100 through the European Medicines Agency's adaptive pathways pilot program.
You may also be interested in...
The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.
The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.